Establishment of ApoE-knockout mouse model of preeclampsia and relevant mechanisms

Experimental and Therapeutic Medicine

Volumn 12, Issue 4, 2016, Pages 2634-2638

  Sun, Wenjuan ^a   Cui, Baoxia ^b   Hong, Fanzhen ^a   Xu, Yongping ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Abnormal lipid metabolism; ApoE knockout mouse; Model of preeclampsia; Soluble fms like tyrosine kinase 1; Toll like receptor 4; Vascular endothelial injury

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; VASCULOTROPIN RECEPTOR 1;

ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; EDEMA; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; GLOMERULUS FILTRATION; LIPID BLOOD LEVEL; LIPID METABOLISM; MOUSE; NECROSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 84988025221     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3678     Document Type: Article

References (16)

1. Gong YH, Jia J, Lü DH, Dai L, Bai Y and Zhou R: Outcome and risk factors of early onset severe preeclampsia. Chin Med J (Engl) 125: 2623-2627, 2012.
2. Yang X, Wang F, Lau WB, Zhang S, Zhang S, Liu H and Ma XL: Autoantibodies isolated from preeclamptic patients induce endothelial dysfunction via interaction with the angiotensin II AT1 receptor. Cardiovasc Toxicol 14: 21-29, 2014.
3. Mannarino E and Pirro M: Endothelial injury and repair: a novel theory for atherosclerosis. Angiology 59 (Suppl 2): 69S-72S, 2008.
4. Podjarny E, Baylis C and Losonczy G: Animal models of preeclampsia. Semin Perinatol 23: 2-13, 1999.
5. Sircar M, Thadhani R and Karumanchi SA: Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 24: 131-138, 2015.
6. Redman CW, Sacks GP and Sargent IL: Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180: 499-506, 1999.
7. Bayhan G, Koçyigit Y, Atamer A, Atamer Y and Akkus Z: Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia. Gynecol Endocrinol 21: 1-6, 2005.
8. Matsuo K, Kooshesh S, Dinc M, Sun CC, Kimura T and Baschat AA: Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol 24: 257-266, 2007.
9. Cekmen MB, Erbagci AB, Balat A, Duman C, Maral H, Ergen K, Ozden M, Balat O and Kuskay S: Plasma lipid and lipoprotein concentrations in pregnancy induced hypertension. Clin Biochem 36: 575-578, 2003.
10. Francoual J, Audibert F, Trioche P, Chalas J, Capel L, Lindenbaum A, Labrune P and Frydman R: Is a polymorphism of the apolipoprotein E gene associated with preeclampsia? Hypertens Pregnancy 21: 127-133, 2002.
11. Belo L, Gaffney D, Caslake M, Santos-Silva A, Pereira-Leite L, Quintanilha A and Rebelo I: Apolipoprotein E and cholesteryl ester transfer protein polymorphisms in normal and preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 112: 9-15, 2004.
12. Kobayashi K, Oyama S, Numata A, Rahman MM and Kumura H: Lipopolysaccharide disrupts the milk-blood barrier by modulating claudins in mammary alveolar tight junctions. PLoS One 8: e62187, 2013.
13. Lee KM and Seong SY: Partial role of TLR4 as a receptor responding to damage-associated molecular pattern. Immunol Lett 125: 31-39, 2009.
14. Banas MC, Banas B, Hudkins KL, Wietecha TA, Iyoda M, Bock E, Hauser P, Pippin JW, Shankland SJ, Smith KD, et al: TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 19: 704-713, 2008.
15. Suzuki H, Ohkuchi A, Matsubara S, Takei Y, Murakami M, Shibuya M, Suzuki M and Sato Y: Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 54: 1129-1135, 2009.
16. Lin M, Yiu WH, Li RX, Wu HJ, Wong DW, Chan LY, Leung JC, Lai KN and Tang SC: The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int 83: 887-900, 2013.